Cameron Drew B, Mustafa Diab Mohamed, Carroll Lauren N, Bollinger Lori A, DeCormier Plosky Willyanne, Levin Carol, Herzel Benjamin, Marseille Elliot, Alexander Lily, Bautista-Arredondo Sergio, Pineda-Antunez Carlos, Cerecero-García Diego, Gomez Gabriela B, Dow William H, Kahn James G
Health Policy and Management, University of California Berkeley, USA.
Institute for Health Policy Studies, University of California San Francisco, USA.
Afr J AIDS Res. 2019 Dec;18(4):277-288. doi: 10.2989/16085906.2019.1679200.
The past decade has seen a growing emphasis on the production of high-quality costing data to improve the efficiency and cost-effectiveness of global health interventions. The need for such data is especially important for decision making and priority setting across HIV services from prevention and testing to treatment and care. To help address this critical need, the Global Health Cost Consortium was created in 2016, in part to conduct a systematic search and screening of the costing literature for HIV and TB interventions in low- and middle-income countries (LMIC). The purpose of this portion of the remit was to compile, standardise, and make publicly available published cost data (peer-reviewed and gray) for public use. We limit our analysis to a review of the quantity and characteristics of published cost data from HIV interventions in sub-Saharan Africa. First, we document the production of cost data over 25 years, including density over time, geography, publication venue, authorship and type of intervention. Second, we explore key methods and reporting for characteristics including urbanicity, platform type, ownership and scale. Although the volume of HIV costing data has increased substantially on the continent, cost reporting is lacking across several dimensions. We find a dearth of cost estimates from HIV interventions in west Africa, as well as inconsistent reporting of key dimensions of cost including platform type, ownership and urbanicity. Further, we find clear evidence of a need for renewed focus on the consistent reporting of scale by authors of costing and cost-effectiveness analyses.
在过去十年中，人们越来越重视高质量成本数据的生成，以提高全球卫生干预措施的效率和成本效益。对于从预防、检测到治疗和护理的整个艾滋病服务领域的决策和优先事项设定而言，此类数据的需求尤为重要。为了满足这一关键需求，全球卫生成本联盟于2016年成立，部分目的是对低收入和中等收入国家（LMIC）的艾滋病和结核病干预措施成本核算文献进行系统检索和筛选。这部分职责的目的是汇编、标准化并公开已发表的成本数据（经过同行评审的和灰色文献）以供公众使用。我们将分析局限于对撒哈拉以南非洲地区艾滋病干预措施已发表成本数据的数量和特征进行综述。首先，我们记录了25年来成本数据的生成情况，包括随时间变化的密度、地理分布、发表渠道、作者身份和干预类型。其次，我们探讨了有关城市性、平台类型、所有权和规模等特征的关键方法及报告情况。尽管非洲大陆的艾滋病成本核算数据量大幅增加，但在几个方面仍缺乏成本报告。我们发现西非艾滋病干预措施的成本估计数据匮乏，而且在成本的关键维度（包括平台类型、所有权和城市性）的报告方面也不一致。此外，我们发现有明确证据表明，成本核算和成本效益分析的作者需要重新关注规模的一致报告。
